SCOTTSDALE, Ariz., Sept. 6, 2023 /PRNewswire/ — Imaging Endpoints (IE), the world leader in cancer trial imaging and one of the world’s largest imaging CROs (iCROs), is pleased to announce the appointment of Manish Sharma, MD, as its chief scientific officer.

Dr. Sharma, a radiologist with more than 20 years of extensive experience in clinical research, medical imaging, and data science, joins Imaging Endpoints with a proven track record of excellence. In addition to having supported the regulatory submission of multiple innovative therapies, including priority review and expedited approvals, his pioneering work in imaging data analysis and utilization of big data for reader performance and variability is industry-leading. . He has also made significant advances in the use of AI/ML techniques, including deep learning applications in radiology imaging.

“Manish’s extensive experience and innovative approach align perfectly with our vision of ‘Connecting Imaging to the Cure,'” said Ronald Korn, MD, PhD, chief medical officer and founder of Imaging Endpoints. “Her leadership in medical and regulatory strategy, including IND, NDA, ANDA, and 505(b)(2) filings, will further enhance the depth and expertise of our blind, independent, central review (BICR) services.” “.

Dr. Sharma will oversee medical and scientific affairs, as well as research and development at Imaging Endpoints. His demonstrated thought leadership, his ability to develop and launch new services, and his world-renowned expertise in clinical trial imaging will be instrumental in accelerating Imaging Endpoints’ leadership, growth, and success.

“Ron Korn is recognized as the industry’s leading expert in clinical trial imaging within oncology and now, with the addition of Manish Sharma, we hope that the combination of their extraordinary talents will enable us to support more oncology trials and regulatory approvals than any other another iCRO ​​in the coming years,” said Doug Dean Burkett, PhD, CEO and President. “Dr. Sharma’s deep experience in clinical trial imaging, excellence in read quality control, and aptitude for advances in data analysis will help us continue to set new standards of excellence as the preferred iCRO ​​partner for enterprises.” biopharmaceuticals around the world.

“Joining Imaging Endpoints is an exciting opportunity to contribute to a leading team that shares my passion for connecting imaging with therapeutic solutions,” said Dr. Sharma. “As clinical trial designs become more complex, innovation plays a crucial role in the industry to harness all available scientific insights from images and metadata for the benefit of sponsors and patients. Through novel methodologies and a commitment to pushing boundaries, I look forward to leveraging my experience to drive innovation and excellence within clinical trial imaging and enhance our support for the most impactful oncology clinical trials around the world.”

About Imaging Endpoints:

Imaging Endpoints (IE) is passionately focused on its vision of connecting imaging to the cure. With an impeccable global inspection record and a 95% marketing authorization success rate, IE has a proven track record of supporting successful regulatory filings around the world. IE’s commitment to quality, innovation and excellence has positioned it as a world leader in oncology imaging. IE’s clients, including the largest, medium and small biopharmaceutical companies, as well as leading CROs, choose IE for its industry-leading science, quality, execution, and remarkable track record of success.

Imaging Endpoints is the largest iCRO ​​focused on oncology, with 8 offices strategically located in 6 countries, including Scottsdale, AZ; Cambridge, MA; London, United Kingdom; Leiden, the Netherlands; Basel, Switzerland; Hyderabad, India; and Shanghai, China.

IE is a subsidiary of HonorHealth, one of the nation’s largest healthcare systems, and also a subsidiary of Southwest Medical Imaging, Ltd. (SMIL/RadPartners), part of the largest private radiology group in the US.

Logo –…

For media inquiries, contact:, no. contact 480.314.3070.

View original content to download multimedia: